Skip to content
NEWSR
Health · 4 min read

What Sugary Drinks May Mean for Stomach Cancer Risk—and What Researchers Still Need to Prove

A reported U.S. association between daily sugary drinks and gastric cancer risk raises practical questions, but the evidence does not prove that beverages cause the disease.

Nora Patel
· Updated
In this story
What Sugary Drinks May Mean for Stomach Cancer Risk—and What Researchers Still Need to Prove

Key takeaways

  • Daily sugary-drink intake was reported as associated with higher gastric cancer risk, not proven to cause it.
  • The supplied primary record is a 2021 systematic review of observational studies, not the directly matching 2026 U.S. study.
  • CDC guidance already links frequent sugary-drink consumption with several established health risks.
  • The key unresolved issue is whether the reported association holds after full methods and participant data are independently reviewed.

A reported association between daily sugar-sweetened beverage intake and gastric cancer could matter to frequent soda and sweetened-drink consumers, but it is not proof that those drinks cause stomach cancer. The central practical trade-off is clearer than the headline: reducing sugary drinks is consistent with existing public-health advice and may improve several established health outcomes, while the size of any stomach-cancer benefit remains uncertain.

What is established about the drinks

The CDC defines sugar-sweetened beverages as drinks containing added sugars, including regular soda, fruit drinks, sports drinks, energy drinks, sweetened waters, and coffee or tea beverages with added sugar. Its guidance says frequent consumption is associated with weight gain, obesity, type 2 diabetes, heart disease, non-alcoholic liver disease, tooth decay, cavities and gout.

That list matters because it places the cancer question in a wider decision. Someone who replaces a sugary drink with water or another unsweetened option may reduce added-sugar and calorie intake, depending on the rest of the diet. The CDC also says that replacing added sugars with low- or no-calorie sweeteners may reduce calories in the short term, while the long-term weight-management effect remains unresolved. That is a trade-off, not a blanket endorsement of any substitute.

What the cancer evidence can—and cannot—say

The linked peer-reviewed record is a systematic review and meta-analysis of observational studies on sweet beverages and cancer risk. Observational research can identify patterns across groups, but it cannot by itself prove that an exposure caused an outcome. People who drink sugary beverages frequently may differ from less frequent consumers in other relevant ways, including diet, weight, medical history or access to care.

A USA TODAY report published Aug. 17, 2026, described a separate U.S. analysis from Mass General Brigham Cancer Institute researchers. It reported that people consuming at least one sugar-sweetened beverage daily had more than twice the risk of gastric cancer compared with people who rarely consumed them. The report said the analysis used decades of data from more than 100,000 people and included regular soda, energy drinks and juice with added sugars.

Those details are not enough to treat the result as a personal forecast. The supplied report says the study group was predominantly White and aged 30 to 75, and that the researchers could not examine associations within racial and ethnic subgroups or among younger adults. It also noted limited information for some participants on health and family history. Those limitations affect how confidently the result can be generalized.

More importantly, the supplied primary URL identifies a 2021 systematic review rather than the full 2026 U.S. study described in the news account. Until the directly matching research paper is available, the reported comparison and its underlying adjustments cannot be checked here against the original methods.

Who is affected by the uncertainty

Frequent consumers are the most obvious audience, but the implications extend to clinicians, public-health agencies, schools, workplaces and families deciding what beverages to make readily available. The CDC already supports limiting sugary drinks for broader health reasons; the emerging gastric-cancer association may add another reason for some people, but it should not be presented as a screening test or diagnosis.

People with a personal or family history of gastric cancer may reasonably want individualized advice, yet the supplied evidence does not establish a special beverage threshold for them. No one should infer that an occasional sugary drink means cancer is likely, or that avoiding these beverages eliminates cancer risk. Gastric cancer has multiple potential influences, and the evidence provided does not quantify the contribution of this one exposure in absolute terms.

The next test for the claim

The most useful next milestone is publication or release of the full peer-reviewed U.S. study. Readers should look for the cohort’s exact size, the number of gastric-cancer cases, how beverage intake was measured, which confounding factors were adjusted for, and whether results were consistent across demographic groups. Researchers would also need to clarify whether the association survives different definitions of daily consumption and beverage type.

For now, the safe evidence-based takeaway is narrower: limiting sugar-sweetened beverages aligns with CDC guidance and may reduce several known health risks. The stomach-cancer finding is a developing observational signal that warrants verification, not a confirmed cause-and-effect rule.

Newsr Reframed

The consequence is practical but limited: reducing sugar-sweetened beverages is already consistent with CDC guidance on added sugar and several established health risks, while the additional stomach-cancer claim remains developing. A 2026 news report described a large U.S. analysis and a more-than-twofold relative association, but the supplied primary record does not match that study and does not provide enough detail to verify the estimate. The next meaningful signal is a directly available peer-reviewed report with case counts, exposure measurements, adjustments and subgroup results. Until then, the finding should guide caution about certainty, not diagnosis or individualized risk prediction.

Sources and methodology

Share this story Facebook X LinkedIn Reddit WhatsApp Email

Latest stories